

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6024501

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	DA-WEI SUN	06/22/2018
RECEIVING PARTY DATA		
Name:	BIOGEN THERAPEUTICS CO., LTD.	
Street Address:	4F, NO. 3, PARK STREET	
Internal Address:	NANGANG DISTRICT	
City:	TAIPEI CITY	
State/Country:	TAIWAN	
Postal Code:	115	
Name:	OSTEOPHARMA INC.	
Street Address:	MF NISHIUMEDA BLDG. 2F-D, 5-1-26,	
Internal Address:	FUKUSHIMA, FUKUSHIMA-KU	
City:	OSAKA	
State/Country:	JAPAN	
Postal Code:	553-0003	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	16079806	
CORRESPONDENCE DATA		
Fax Number:	(202)371-2540	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 371-2600	
Email:	sschalle@sternekessler.com, kperry@sternekessler.com	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
Address Line 1:	1100 NEW YORK AVENUE	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	3902.0010001	
NAME OF SUBMITTER:	SCOTT A. SCHALLER	
SIGNATURE:	/Scott A. SCHALLER, #60,167/	

DATE SIGNED:	03/20/2020
Total Attachments: 3 source=2020-03-20-Assignment-3902-0010001#page1.tif source=2020-03-20-Assignment-3902-0010001#page2.tif source=2020-03-20-Assignment-3902-0010001#page3.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned inventor: **Da-Wei SUN** hereby sells and assigns to **BioGend Therapeutics Co., Ltd.**, a corporation formed under the laws of Taiwan, whose mailing address is 4F., No. 3, Park St., Nangang Dist., Taipei, 115, Taiwan (R.O.C), and **Osteopharma Inc.**, a corporation formed under the laws of Japan, whose mailing address is MF Nishiumeda Bldg, 2F-D, 5-1-26, Fukushima, Fukushima-ku, Osaka 553-0003, Japan, (BioGend Therapeutics Co., Ltd. and Osteopharma Inc. are hereafter referred to as the Assignees), his entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) any and all inventions described and/or claimed in International Application No. PCT/IB2017/058516, filed on December 29, 2017 and entitled "**Recombinant Polypeptides and Nucleic Acid Molecules, Compositions, and Methods of Making and Uses Thereof**";

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), filed in any country, including continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals, reexaminations, Letters Patents (to the full extent of the term or terms for which Letters Patents issue), and Supplemental Protection Certificates, resulting from and/or claiming priority to any of the foregoing; and

(c) in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals, and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignees, their successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignees may deem necessary or expedient.

The undersigned inventor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, or reexamination application(s) thereof and to cooperate with the Assignees in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor hereby represents that he has full right to convey the entire interest herein assigned, and that he has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor hereby represents that he understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventor.

IN WITNESS WHEREOF, executed by the undersigned inventor on the date opposite his name.

Date: 2018/6/22


Signature of Inventor: _____



Da-Wei SUN

ACCEPTED AND AGREED TO BY THE ASSIGNEES,

BioGend Therapeutics Co., Ltd.


By: 

Name: Te-Li Chen

Title: Chairman of BioGend Therapeutics

Date: Jun 28, 2018

Osteopharma Inc.

By: 

Name: Shiro Jochi

Title: President of Osteopharma Inc.

Date: Jun 25, 2018

9494191.1